Gene therapy trial for cerebral palsy and HIE
Part of Brain & nervous system, Heart & circulation, Mental health clinical trials.
This trial tests a gene therapy given as a nose spray for people with cerebral palsy or HIE. It aims to see if the treatment is safe and helps improve movement over two years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 65 years old.
- You must have a doctor's diagnosis of HIE (brain injury from lack of oxygen at birth), confirmed by medical records or MRI.
- Your health must be stable for at least 6 months (no major surgeries or hospital stays related to HIE).
- You must have a moderate level of movement problems (GMFM score between 40% and 70%).
- You must have already received or are now getting the study gene therapy nose spray at a participating clinic.
- Your parent or guardian must agree to take part in this registry and let your data be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intensive therapy program designed to help children with brain-based conditions like cerebral palsy or autism improve their skills in movement, thinking, and daily activities. The program runs for 2 weeks with daily sessions, and researchers will check for changes in your child's abilities.
This trial tests a one-time gene therapy (BFB-101) for children with SPG47, a genetic condition that affects movement and brain function. The therapy aims to deliver a working copy of the AP4B1 gene to help slow or stop the disease's progression.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
This trial tests a gene therapy for people with a specific mutation (S295L) in the SLC6A1 gene, which causes a neurodevelopmental disorder. The therapy aims to correct the genetic issue, and participants will be monitored closely for safety and effectiveness.
This trial tests a gene therapy given by a one-time injection into the spinal fluid for children with Mucolipidosis type IV. It aims to see if the therapy is safe and can help slow or stop the disease.
This trial tests a new gene therapy treatment designed to help the body process certain amino acids better in infants with propionic acidemia. The therapy uses a modified virus to deliver a working copy of a faulty gene, potentially reducing dangerous acid buildups and hospital visits.
Hear when a new Hypoxic Ischemic Encephalopathy of Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.